Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02755181 · ClinicalTrials.gov registry record
fMRI in Impulsivity
A clinical trial of Borderline Personality Disorder and Impulse Control Disorders, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 48
- Enrollment target
- 1
- Study location
NCT02755181 is a study of Borderline Personality Disorder and Impulse Control Disorders that has completed, run by Boehringer Ingelheim. The registered enrollment target is 48 participants, below the 105-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02755181, a study of Borderline Personality Disorder and Impulse Control Disorders, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to use resting-state and task based functional Magnetic Resonance Imaging (fMRI) as a tool to evaluate trait characteristics of impulsivity in subjects with borderline personality disorder.
Conditions Studied
Interventions
- BEHAVIORAL Experimental
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-07-22 |
| Est. Completion | 2018-05-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02755181
The ClinicalTrials.gov registry entry for NCT02755181 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (54% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Borderline Personality Disorder appearing as the primary indexed condition, and to 1 intervention - of which Experimental is the first listed.
NCT02755181 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT02755181 about?
NCT02755181 is a clinical study titled "fMRI in Impulsivity". This study aims to use resting-state and task based functional Magnetic Resonance Imaging (fMRI) as a tool to evaluate trait characteristics of impulsivity in subjects with borderline personality disorder.
What is the current status of trial NCT02755181?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2016-07-22. Estimated completion is 2018-05-30.
What conditions does trial NCT02755181 study?
This clinical trial studies the following conditions: Borderline Personality Disorder, Impulse Control Disorders.
What interventions are being tested in trial NCT02755181?
The interventions under investigation include: Experimental (BEHAVIORAL).
Who is sponsoring clinical trial NCT02755181?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02755181 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Personality Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MDMA in Borderline Personality Disorder
RECRUITING · Phase 2
-
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
RECRUITING · NA
-
Cognitive Reappraisal Training for Borderline Personality (BPD)
RECRUITING · NA
-
Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder
RECRUITING · Phase 2
-
Treatment of Borderline Personality Disorder With rTMS
RECRUITING · NA
-
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.